8月5日，达维塔保健盘后下跌6.14%，报213.99美元/股，成交额3781.36万美元。
消息面上，公司发布Q2财报，调整后每股收益4.02美元，超出市场预期的3.88美元，同比增长36.27%；营收35.54亿美元，高于预期的34.96亿美元。然而，公司维持全年调整后EPS指引为14.10-15.20美元不变，指引中值14.65美元低于FactSet一致预期的14.88美元。考虑到Q1和Q2连续大幅超预期（Q1 EPS 2.87美元远超预期2.32美元），市场此前对公司上调全年指引抱有较高期待，指引维持不变被视为隐含下半年盈利增速放缓信号，引发盘后抛压。
达维塔保健是一家专注于肾脏护理的领先医疗服务提供商，拥有超过25年经验，运营透析中心并提供家庭护理支持服务。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.